Aprinoia Therapeutics (Aprinoia Therapeutics) Scaled Net Operating Assets : -13.13 (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aprinoia Therapeutics's operating assets for the quarter that ended in Jun. 2023 was $6.75 Mil. Aprinoia Therapeutics's operating liabilities for the quarter that ended in Jun. 2023 was $80.81 Mil. Aprinoia Therapeutics's Total Assets for the quarter that ended in Dec. 2022 was $5.64 Mil. Therefore, Aprinoia Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2023 was -13.13.

Aprinoia Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Aprinoia Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Scaled Net Operating Assets Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Scaled Net Operating Assets

-4.48

-5.79

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Scaled Net Operating Assets	-4.48	-	-	-13.13

Competitive Comparison of Aprinoia Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Aprinoia Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Scaled Net Operating Assets falls into.

Aprinoia Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aprinoia Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2022 )
=	(Operating Assets (A: Dec. 2022 )	-	Operating Liabilities (A: Dec. 2022 ))	/	Total Assets (A: Dec. 2021 )
=	(4.422	-	78.384)	/	12.766
=	-5.79

where

	Operating Assets		(A: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	5.643	-	1.221
=	4.422

	Operating Liabilities		(A: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	81.093	-	0.042	-	2.667
=	78.384

Aprinoia Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Jun. 2023 )
=	(Operating Assets (Q: Jun. 2023 )	-	Operating Liabilities (Q: Jun. 2023 ))	/	Total Assets (Q: Dec. 2022 )
=	(6.745	-	80.813)	/	5.643
=	-13.13

where

	Operating Assets		(Q: Jun. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	14.476	-	7.731
=	6.745

	Operating Liabilities		(Q: Jun. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	96.408	-	0.015	-	15.58
=	80.813

Aprinoia Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines